36 Participants Needed

DB-3Q for Crohn's Disease

EV
Overseen ByExecutive Vice President, Clinical Affairs, MS
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Direct Biologics, LLC
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a double-blind, randomized, placebo-controlled, sequential cohort, ascending dose clinical trial to evaluate the safety and determine the efficacy of ascending doses of DB-3Q for the treatment of Perianal Fistulizing Crohn's Disease.

Are You a Good Fit for This Trial?

This trial is for individuals with Perianal Fistulizing Crohn's Disease who have tried and failed at least one medical therapy in the past year, including antibiotics or monoclonal antibodies. Participants must have stable medical therapy for Crohn's Disease for two months prior to starting the trial, one or two actively draining perianal fistulas, and either a history of unsuccessful surgery or are not candidates/willing to undergo surgery.

Inclusion Criteria

I have signed the consent form.
My Crohn's disease treatment has been stable for at least 2 months.
I have 1 or 2 actively draining perianal fistulas.
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive a single dose of DB-3Q or placebo for the treatment of Perianal Fistulizing Crohn's Disease

12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • DB-3Q
Trial Overview The study tests DB-3Q versus a placebo in treating Perianal Fistulizing Crohn's Disease. It’s double-blind (neither doctors nor patients know who gets what), randomized (assigned by chance), placebo-controlled (compared with inactive substance), and doses increase over time to find both safety and effectiveness.
How Is the Trial Designed?
6Treatment groups
Experimental Treatment
Placebo Group
Group I: Single dose DB-3Q 30 mL direct injectionExperimental Treatment1 Intervention
Group II: Single dose DB-3Q 15 ml IV and DB-3Q 30 mL direct injectionExperimental Treatment1 Intervention
Group III: Single dose DB-3Q 15 mL direct injectionExperimental Treatment1 Intervention
Group IV: Single dose Placebo 15 ml IV and Placebo 30 mL direct injectionPlacebo Group1 Intervention
Group V: Single dose Placebo 15 mL direct injectionPlacebo Group1 Intervention
Group VI: Single dose Placebo 30 mL direct injectionPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Direct Biologics, LLC

Lead Sponsor

Trials
11
Recruited
1,100+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security